Objective: The aim of this study is to evaluate the influence of endogenous testosterone density (ETD) on features of aggressive prostate cancer (PCa) in intermediate-risk disease treated with radical prostatectomy and extended pelvic lymph node dissection. Materials and Methods: Density measurements included the ratio of endogenous testosterone (ET), prostate-specific antigen (PSA), and percentage of biopsy positive cores (BPC) on prostate volume (ETD, PSAD, and BPCD, respectively). The ratio of percentage of cancer invading the gland (tumor load, TL) on prostate weight (TLD) was also calculated. Unfavorable disease (UD) was defined as tumor upgrading (ISUP >3) and/or upstaging (pT >2) and/or lymph node invasion (LNI). Associations of ETD with features of aggressive PCa, including UD and TLD, were evaluated by logistic and linear regression models. Results: Evaluated cases were 338. Subjects with upgrading, upstaging, and LNI were 61/338 (18%), 73/338 (21%), and 25/338 (7.4%), respectively. TLD correlated with UD (Pearson’s correlation coefficient, r = 0.204; p < 0.0001), PSAD (r = 0.342; p < 0.0001), BPCD (r = 0.364; p < 0.0001), and ETD (r = 0.214; p < 0.0001), which also correlated with BMI (r = −0.223; p < 0.0001), PSAD (r = 0.391; p < 0.0001), and BPCD (r = 0.407; p < 0.0001). TLD was the strongest independent predictor of UD (OR = 2.244; 95% CI = 1.146–4.395; p = 0.018). In the multivariate linear regression model predicting BPCD, ETD was an independent predictor (linear regression coefficient, b = 0.026; 95% CI: 0.016–0.036; p < 0.0001) together with PSAD (b = 1.599; 95% CI: 0.863–2.334; p < 0.0001) and TLD (b = 0.489; 95% CI: 0.274–0.706; p < 0.0001). According to models, TLD increased as ETD increased accordingly, but mean ET levels were significantly lower for patients with UD. Conclusions: As ETD measurements incremented, the risk of large tumors extending beyond the prostate increased accordingly, and patients with lower ET levels were more likely to occult UD. The influence of ETD on PCa biology should be addressed by prospective studies.

1.
Mottet
N
,
van den Bergh
RCN
,
Briers
E
,
Van den Broeck
T
,
Cumberbatch
MG
,
De Santis
M
,
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
.
Eur Urol
.
2021 Feb
;
79
(
2
):
243
62
.
2.
Carroll
PH
,
Mohler
JL
.
NCCN guidelines updates: prostate cancer and prostate cancer early detection
.
J Natl Compr Canc Netw
.
2018 May
;
16
(
5S
):
620
3
. .
3.
Artibani
W
,
Porcaro
AB
,
De Marco
V
,
Cerruto
MA
,
Siracusano
S
.
Management of biochemical recurrence after primary curative treatment for prostate cancer: a review
.
Urol Int
.
2018
;
100
(
3
):
251
62
. .
4.
Stolzenbach
LF
,
Nocera
L
,
Collà-Ruvolo
C
,
Tian
Z
,
Knipper
S
,
Maurer
T
,
Improving the stratification of patients with intermediate-risk prostate cancer
.
Clin Genitourin Cancer
.
2021 Apr
;
19
(
2
):
e120
e128
.
5.
Su
ZT
,
Patel
HD
,
Epstein
JI
,
Pavlovich
CP
,
Allaf
ME
.
Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: comparison of outcomes and predictors to identify potential candidates for active surveillance
.
Cancer
.
2020 Apr 15
;
126
(
8
):
1632
9
. .
6.
Ploussard
G
,
Isbarn
H
,
Briganti
A
,
Sooriakumaran
P
,
Surcel
CI
,
Salomon
L
,
Members of the prostate cancer working group of the young academic urologists working party of the European association of urology. Can we expand active surveillance criteria to include biopsy Gleason 3 + 4 prostate cancer? A multi-institutional study of 2,323 patients
.
Urol Oncol
.
2015 Feb
;
33
(
2
):
71.e1
9
.
7.
Yang
DD
,
Mahal
BA
,
Muralidhar
V
,
Nezolosky
MD
,
Vastola
ME
,
Labe
SA
,
Risk of upgrading and upstaging among 10,000 patients with gleason 3 + 4 favorable intermediate-risk prostate cancer
.
Eur Urol Focus
.
2019 Jan
;
5
(
1
):
69
76
.
8.
Porcaro
AB
,
Amigoni
N
,
Tafuri
A
,
Rizzetto
R
,
Shakir
A
,
Tiso
L
,
Endogenous testosterone as a predictor of prostate growing disorders in the aging male
.
Int Urol Nephrol
.
2021 May
;
53
(
5
):
843
54
.
9.
Tafuri
A
,
Amigoni
N
,
Rizzetto
R
,
Sebben
M
,
Shakir
A
,
Gozzo
A
,
Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate- and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection
.
Int Urol Nephrol
.
2020 Nov
;
52
(
11
):
2097
105
.
10.
Porcaro
AB
,
Tafuri
A
,
Sebben
M
,
Processali
T
,
Pirozzi
M
,
Amigoni
N
,
High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection
.
Asian J Androl
.
2020 May
;
22
(
3
):
323
9
.
11.
Porcaro
AB
,
Tafuri
A
,
Sebben
M
,
Processali
T
,
Pirozzi
M
,
Shakir
A
,
Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy
.
Int Urol Nephrol
.
2019 Dec
;
51
(
12
):
2169
80
.
12.
Porcaro
AB
,
Cacciamani
GE
,
Sebben
M
,
Tafuri
A
,
Processali
T
,
Rizzetto
R
,
Lymph nodes invasion of marcille’s fossa associates with high metastatic load in prostate cancer patients undergoing extended pelvic lymph node dissection: the role of marcillectomy
.
Urol Int
.
2019
;
103
(
1
):
25
32
.
13.
Cacciamani
GE
,
Porcaro
AB
,
Sebben
M
,
Tafuri
A
,
Rizzetto
R
,
De Luyk
N
,
Extended pelvic lymphadenectomy for prostate cancer: should the Cloquet’s nodes dissection be considered only an option?
Minerva Urol Nefrol
.
2019 Apr
;
71
(
2
):
136
45
.
14.
van der Kwast
TH
,
Amin
MB
,
Billis
A
,
Epstein
JI
,
Griffiths
D
,
Humphrey
PA
,
ISUP prostate cancer group. International society of urological pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 2: T2 substaging and prostate cancer volume
.
Mod Pathol
.
2011 Jan
;
24
(
1
):
16
25
.
15.
Epstein
JI
,
Feng
Z
,
Trock
BJ
,
Pierorazio
PM
.
Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades
.
Eur Urol
.
2012 May
;
61
(
5
):
1019
24
. .
16.
Pierorazio
PM
,
Walsh
PC
,
Partin
AW
,
Epstein
JI
.
Prognostic gleason grade grouping: data based on the modified gleason scoring system
.
BJU Int
.
2013 May
;
111
(
5
):
753
60
. .
17.
Epstein
JI
,
Egevad
L
,
Amin
MB
,
Delahunt
B
,
Srigley
JR
,
Humphrey
PA
,
The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system
.
Am J Surg Pathol
.
2016 Feb
;
40
(
2
):
244
52
. .
18.
Zumsteg
ZS
,
Spratt
DE
,
Pei
I
,
Zhang
Z
,
Yamada
Y
,
Kollmeier
M
,
A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy
.
Eur Urol
.
2013 Dec
;
64
(
6
):
895
902
.
19.
Martin
NE
,
Chen
MH
,
Zhang
D
,
Richie
JP
,
D’Amico
AV
.
Unfavorable intermediate-risk prostate cancer and the odds of upgrading to gleason 8 or higher at prostatectomy
.
Clin Genitourin Can
.
2017 Apr
;
15
(
2
):
237
41
. .
20.
Weingärtner
K
,
Ramaswamy
A
,
Bittinger
A
,
Gerharz
EW
,
Vöge
D
,
Riedmiller
H
.
Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic
.
J Urol
.
1996 Dec
;
156
(
6
):
1969
71
. .
21.
Klap
J
,
Schmid
M
,
Loughlin
KR
.
The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy
.
J Urol
.
2015 Feb
;
193
(
2
):
403
13
. .
22.
Lopez
DS
,
Advani
S
,
Tsilidis
KK
,
Wang
R
,
Canfield
S
.
Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk?
Transl Androl Urol
.
2017 Jun
;
6
(
3
):
566
79
. .
23.
Loughlin
KR
.
The testosterone conundrum: the putative relationship between testosterone levels and prostate cancer
.
Urol Oncol
.
2016 Nov
;
34
(
11
):
482
e4
. .
24.
Watts
EL
,
Appleby
PN
,
Albanes
D
,
Black
A
,
Chan
JM
,
Chen
C
,
Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men
.
PLoS One
.
2017 Dec 27
;
12
(
12
):
e0187741
.
25.
Morgentaler
A
,
Traish
AM
.
Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth
.
Eur Urol
.
2009 Feb
;
55
(
2
):
310
20
. .
26.
Pechersky
AV
.
The influence of partial androgen deficiency in aging men (PADAM) on the development of benign prostatic hyperplasia and prostate cancer
.
Am Res J Urol
.
2019
;
31
:
1
16
.
27.
Tafuri
A
,
Porcaro
AB
,
Shakir
A
,
Migliorini
F
,
Verratti
V
,
Brunelli
M
,
Serum testosterone and obesity in prostate cancer biology: a call for health promotion in the ageing male
.
Aging Clin Exp Res
.
2021 May
;
33
(
5
):
1399
401
.
28.
Brambilla
DJ
,
Matsumoto
AM
,
Araujo
AB
,
McKinlay
JB
.
The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men
.
J Clin Endocrinol Metab
.
2009 Mar
;
94
(
3
):
907
13
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.